Abstract
PET quantification in neuropsychiatry focuses on the quantification of dynamic brain PET data. Starting from the basics of dynamic PET imaging, different methodologies are presented to extract time-dependent activity concentration for specific brain regions, both manually and automatically. The latter methodology uses predefined VOI templates and has the advantage of being operator independent. Once time-activity curves are available for the brain regions of interest, kinetic modeling is described using different compartmental models. These compartments represent the different states of the radiotracer such as the bound state. This way, the PET signal of specifically tracer can be separated from tracer that is free or nonspecifically bound. In this context, quantitative endpoints such as distribution volume and binding potential are discussed. Next to compartment modeling, graphical analysis techniques for reversible and irreversible tracer kinetics are discussed. These techniques are computational efficient and therefore suitable for creating parametric image data. These parametric image data allow voxel-wise statistical comparison of dynamic PET data. In terms of different options for the input function which is needed for tracer kinetic modeling, we discuss different possibilities including a reference tissue model. Finally, we elaborate on the advantages and limitations of a bolus/constant infusion approach to quantify tracer uptake under steady-state conditions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alf MF, Wyss MT, Buck A et al (2013) Quantification of brain glucose metabolism by 18F-FDG PET with real-time arterial and image-derived input function in mice. J Nucl Med 54:132–138. doi:10.2967/jnumed.112.107474
Backes H, Ullrich R, Neumaier B et al (2009) Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 36:1960–1967. doi:10.1007/s00259-009-1244-4
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520. doi:10.1124/pr.58.3.5.488
Brock CS, Young H, Osman S et al (2005) Glucose metabolism in brain tumours can be estimated using [18F]2-fluorodeoxyglucose positron emission tomography and a population-derived input function scaled using a single arterialised venous blood sample. Int J Oncology 26:1377–1383
Carson RE, Breier A, De Bartolomeis A et al (1997) Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17:437–447. doi:10.1097/00004647-199704000-00009
Casteels C, Koole M, Celen S et al (2012) Preclinical evaluation and quantification of [18F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imaging 39:1467–1477. doi:10.1007/s00259-012-2163-3
Celen S, Koole M, De Angelis M et al (2010) Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 51:1584–1591. doi:10.2967/jnumed.110.077040
Crone C (1963) The permeability of capillaries in various organs as determined by use of the “indicator diffusion” method. Acta Physiol Scand 58:292–305
De Klerk OL, Willemsen ATM, Roosink M et al (2009) Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood–brain barrier. Int J Neuropsychopharmacol 12:895–904. doi:10.1017/S1461145709009894
De Klerk OL, Willemsen ATM, Bosker FJ et al (2010) Regional increase in P-glycoprotein function in the blood–brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res 183:151–156. doi:10.1016/j.pscychresns.2010.05.002
Doorduin J, De Vries EFJ, Willemsen ATM et al (2009) Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50:1801–1807. doi:10.2967/jnumed.109.066647
Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science (New York, NY) 338:68–72. doi:10.1126/science.1222939
Enzi B, Duncan NW, Kaufmann J et al (2012) Glutamate modulates resting state activity in the perigenual anterior cingulate cortex – a combined fMRI-MRS study. Neuroscience 227:102–109. doi:10.1016/j.neuroscience.2012.09.039
Frackowiak RS, Lenzi GL, Jones T, Heather JD (1980) Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr 4:727–736
Fujishige K, Kotera J, Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266:1118–1127
Gérard N, Pieters G, Goffin K et al (2011) Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry 70:777–784. doi:10.1016/j.biopsych.2011.05.010
Grauer SM, Pulito VL, Navarra RL et al (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, Cognitive, and Negative Symptoms of schizophrenia. J Pharmacol Exp Ther 331:574–590. doi:10.1124/jpet.109.155994
Greicius M (2008) Resting-state functional connectivity in neuropsychiatric disorders. Curr Opin Neurol 21:424–430. doi:10.1097/WCO.0b013e328306f2c5
Hebb ALO, Robertson HA (2007) Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 7:86–92. doi:10.1016/j.coph.2006.08.014
Hebb A, Robertson H, Denovan-Wright E (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967–981. doi:10.1016/j.neuroscience.2003.11.009
Hirvonen J, Zanotti-Fregonara P, Umhau JC et al (2012) Reduced cannabinoid CB(1) receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry. doi:10.1038/mp.2012.100
Hume SP, Myers R, Bloomfield PM et al (1992) Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse (New York, NY) 12:47–54. doi:10.1002/syn.890120106
Ichise M, Toyama H, Innis RB, Carson RE (2002) Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22:1271–1281. doi:10.1097/00004647-200210000-00015
Ichise M, Liow J-S, Lu J-Q et al (2003) Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096–1112. doi:10.1097/01.WCB.0000085441.37552.CA
Innis RB, Carson R (2007) Consensus nomenclature: its time has come. Eur J Nucl Med Mol Imaging 34:1239. doi:10.1007/s00259-007-0481-7
Kendell SF, Krystal JH, Sanacora G (2005) GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 9:153–168. doi:10.1517/14728222.9.1.153
Kenneth LD, Dennis C, Joseph TC, Nemeroff C (2002) Neuropsychopharmacology—the fifth generation of progress, first edit. 2080. In: Davis KL, Charney D, Coyle JT, Nemeroff Lippincott C (eds), Williams and Wilkins: Philadelphia, 2002. ISBN: 0-7817-2837-1
Kety SS, Schmidt CF (1948) The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Clin Invest 27:476–483. doi:10.1172/JCI101994
Kim J-J, Park H-J, Jung Y-C et al (2009) Evaluative processing of ambivalent stimuli in patients with schizophrenia and depression: a [15O] H2O PET study. J Int Neuropsychol Soc 15:990–1001. doi:10.1017/S1355617709990403
Kühn S, Gallinat J (2013) Resting-state brain activity in schizophrenia and major depression: a quantitative meta-analysis. Schizophr Bull 39:358–365. doi:10.1093/schbul/sbr151
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158. doi:10.1006/nimg.1996.0066
Lammertsma AA, Bench CJ, Hume SP et al (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42–52. doi:10.1097/00004647-199601000-00005
Logan J, Fowler JS, Volkow ND et al (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740–747. doi:10.1038/jcbfm.1990.127
Logan J, Alexoff D, Fowler JS (2011) The use of alternative forms of graphical analysis to balance bias and precision in PET images. J Cereb Blood Flow Metab 31:535–546. doi:10.1038/jcbfm.2010.123
Lopresti BJ, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972
Lucignani G, Schmidt KC, Moresco RM et al (1993) Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. J Nucl Med 34:360–369
Luyten L, Casteels C, Vansteenwegen D et al (2012) Micro-positron emission tomography imaging of rat brain metabolism during expression of contextual conditioning. J Neurosci 32:254–263. doi:10.1523/JNEUROSCI.3701-11.2012
Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670. doi:10.1038/nrd2058
Mourik JEM, Lubberink M, Schuitemaker A et al (2009) Image-derived input functions for PET brain studies. Eur J Nucl Med Mol Imaging 36:463–471. doi:10.1007/s00259-008-0986-8
Nishi A, Kuroiwa M, Miller DB et al (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460–10471. doi:10.1523/JNEUROSCI.2518-08.2008
Phelps ME, Huang SC, Hoffman EJ et al (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6:371–388. doi:10.1002/ana.410060502
Pinborg LH, Videbaek C, Knudsen GM et al (2000) Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse (New York, NY) 36:322–329, doi:10.1002/(SICI)1098-2396(20000615)36:4<322::AID-SYN9>3.0.CO;2-W
Puts NAJ, Edden RAE (2012) In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc 60:29–41. doi:10.1016/j.pnmrs.2011.06.001
Renkin EM (1959) Exchangeability of tissue potassium in skeletal muscle. Am J Physiol 197:1211–1215
Rousset O, Rahmim A, Alavi A, Zaidi H (2007) Partial volume correction strategies in PET. PET Clin 2:235–249. doi:10.1016/j.cpet.2007.10.005
Sanabria-Bohórquez S (2003) Image-derived input function for [11C]flumazenil kinetic analysis in human brain. Mol Imaging Biol 5:72–78. doi:10.1016/S1536-1632(03)00046-5
Sanabria-Bohórquez SM, Labar D, Levêque P et al (2000) [11C]flumazenil metabolite measurement in plasma is not necessary for accurate brain benzodiazepine receptor quantification. Eur J Nucl Med 27:1674–1683
Sanabria-Bohórquez SM, Hamill TG, Goffin K et al (2010) Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging 37:920–933. doi:10.1007/s00259-009-1340-5
Sanabria-Bohórquez SM, Joshi AD, Holahan M et al (2012) Quantification of the glycine transporter 1 in rhesus monkey brain using [18F]MK-6577 and a model-based input function. Neuroimage 59:2589–2599. doi:10.1016/j.neuroimage.2011.08.080
Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63–77. doi:10.1016/j.neuropharm.2011.07.036
Savitz JB, Drevets WC (2013) Neuroreceptor imaging in depression. Neurobiol Dis 52:49–65. doi:10.1016/j.nbd.2012.06.001
Seeger TF, Bartlett B, Coskran TM et al (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113–126
Siuciak JA, Strick CA (2006) Treating neuropsychiatric disorders with PDE10A inhibitors. Drug Discov Today Ther Strateg 3:527–532. doi:10.1016/j.ddstr.2006.10.012
Smith DF, Jakobsen S (2009) Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 19:611–628. doi:10.1016/j.euroneuro.2009.04.005
Surmeier DJ, Ding J, Day M et al (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228–235. doi:10.1016/j.tins.2007.03.008
Svarer C, Madsen K, Hasselbalch SG et al (2005) MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 24:969–979. doi:10.1016/j.neuroimage.2004.10.017
Takagi S, Takahashi W, Shinohara Y et al (2004) Quantitative PET cerebral glucose metabolism estimates using a single non-arterialized venous-blood sample. Ann Nucl Med 18:297–302
Thie JA (1994) Clarification of a fractional uptake concept. Comment on Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med. 36(4):711–712
Tu Z, Fan J, Li S et al (2011) Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem 19:1666–1673. doi:10.1016/j.bmc.2011.01.032
Van Laere K, De Hoon J, Bormans G et al (2012) Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther 92:243–250. doi:10.1038/clpt.2012.62
Van Laere K, Ahmad RU, Hudyana H et al (2013) Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging 40:254–261. doi:10.1007/s00259-012-2270-1
Visser AK, Ramakrishnan NK, Willemsen AT et al (2013). [11C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain. J Cereb Blood Flow Metab. doi:10.1038/jcbfm.2013.171. [Epub ahead of print]
Visser AKD, Van Waarde A, Willemsen ATM et al (2011) Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications. Eur J Nucl Med Mol Imaging 38:576–591. doi:10.1007/s00259-010-1663-2
Visvikis D, Francis D, Mulligan R et al (2004) Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 31:169–178. doi:10.1007/s00259-003-1339-2
Walter M, Henning A, Grimm S et al (2009) The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66:478–486. doi:10.1001/archgenpsychiatry.2009.39
Watabe H, Endres CJ, Breier A et al (2000) Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 41:522–530
Wong DF, Kuwabara H, Horti AG et al (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52:1505–1513. doi:10.1016/j.neuroimage.2010.04.034
Zanotti-Fregonara P, Fadaili EM, Maroy R et al (2009) Comparison of eight methods for the estimation of the image-derived input function in dynamic [(18)F]-FDG PET human brain studies. J Cereb Blood Flow Metab 29:1825–1835. doi:10.1038/jcbfm.2009.93
Zanotti-Fregonara P, Chen K, Liow J-S et al (2011a) Image-derived input function for brain PET studies: many challenges and few opportunities. J Cereb Blood Flow Metab 31:1986–1998. doi:10.1038/jcbfm.2011.107
Zanotti-Fregonara P, Liow J-S, Fujita M et al (2011b) Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28. PLoS One 6:e17056. doi:10.1371/journal.pone.0017056
Zanotti-Fregonara P, Zoghbi SS, Liow J-S et al (2011c) Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function. Neuroimage 54:1903–1909. doi:10.1016/j.neuroimage.2010.10.064
Zanotti-Fregonara P, Hines CS, Zoghbi SS et al (2012) Population-based input function and image-derived input function for [11C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. Neuroimage 63:1532–1541. doi:10.1016/j.neuroimage.2012.08.007
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Koole, M., Casteels, C., Van Laere, K. (2014). PET Quantification in Neuropsychiatry. In: Dierckx, R., Otte, A., de Vries, E., van Waarde, A., den Boer, J. (eds) PET and SPECT in Psychiatry. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40384-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-40384-2_2
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40383-5
Online ISBN: 978-3-642-40384-2
eBook Packages: MedicineMedicine (R0)